Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010, Article ID 676284, 5 pages
http://dx.doi.org/10.1155/2010/676284
Review Article

Cytokine Networks in Systemic Lupus Erythematosus

1Graduate School of Frontier Biosciences, Osaka University, Suita, Osaka 565-0871, Japan
2Laboratory of Immune Regulation, Wakayama Medical University, 105 Saito Bio Innovation Center, 7-7-20 Saito-Asagi, Ibaraki, Osaka 567-0085, Japan

Received 9 February 2010; Accepted 21 March 2010

Academic Editor: Brian Poole

Copyright © 2010 Hooi-Ming Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. L. Kotzin, “Systemic lupus erythematosus,” Cell, vol. 85, no. 3, pp. 303–306, 1996. View at Publisher · View at Google Scholar · View at Scopus
  2. M. J. Rood, E. A. van der Velde, R. Ten Cate, F. C. Breedveld, and T. W J Huizinga, “Female sex hormones at the onset of systemic lupus erythematosus affect survival,” British Journal of Rheumatology, vol. 37, no. 9, pp. 1008–1010, 1998. View at Google Scholar · View at Scopus
  3. L. Steinman, “A brief history of TH17, the first major revision in the TH1/TH2 hypothesis of T cell-mediated tissue damage,” Nature Medicine, vol. 13, no. 2, pp. 139–145, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. M. Al-Janadi, S. Al-Balla, A. Al-Dalaan, and S. Raziuddin, “Cytokine profile in systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases,” Journal of Clinical Immunology, vol. 13, no. 1, pp. 58–67, 1993. View at Publisher · View at Google Scholar · View at Scopus
  5. G. S. Dean, J. Tyrrell-Price, E. Crawley, and D. A. Isenberg, “Cytokines and systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 59, no. 4, pp. 243–251, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. D. Emilie, L. Llorente, and P. Galanaud, “Cytokines and systemic lupus erythematosus,” Annales de Medecine Interne, vol. 147, no. 7, pp. 480–484, 1996. View at Google Scholar · View at Scopus
  7. E. M. Davas, A. Tsirogianni, I. Kappou, D. Karamitsos, I. Economidou, and P. C. Dantis, “Serum IL-6, TNFα, p55 srTNFα, p75 srTNFα, srIL-2α levels and disease activity in systemic lupus erythematosus,” Clinical Rheumatology, vol. 18, no. 1, pp. 17–22, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Sabry, H. Sheashaa, A. El-Husseini et al., “Proinflammatory cytokines (TNF-α and IL-6) in Egyptian patients with SLE: its correlation with disease activity,” Cytokine, vol. 35, no. 3-4, pp. 148–153, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. C. Gabay, N. Cakir, F. Moral et al., “Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity,” The Journal of Rheumatology, vol. 24, no. 2, pp. 303–308, 1997. View at Google Scholar · View at Scopus
  10. B. K. Pelton, W. Hylton, and A. M. Denman, “Activation of IL-6 production by UV irradiation of blood mononuclear cells from patients with systemic lupus erythematosus,” Clinical and Experimental Immunology, vol. 89, no. 2, pp. 251–254, 1992. View at Google Scholar · View at Scopus
  11. J. K. Lacki, P. Leszczynski, J. Kelemen, W. Müller, and S. H. Mackiewicz, “Cytokine concentration in serum of lupus erythematosus patients: the effect on acute phase response,” Journal of Medicine, vol. 28, no. 1-2, pp. 99–107, 1997. View at Google Scholar · View at Scopus
  12. J. F. Viallard, J. L. Pellegrin, V. Ranchin et al., “Th1 (IL-2, interferon-gamma (IFN-γ)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE),” Clinical and Experimental Immunology, vol. 115, no. 1, pp. 189–195, 1999. View at Publisher · View at Google Scholar · View at Scopus
  13. A. M. Beebe, D. J. Cua, and R. de Waal Malefyt, “The role of interleukin-10 in autoimmune disease: systemic lupus erythematosus (SLE) and multiple sclerosis (MS),” Cytokine and Growth Factor Reviews, vol. 13, no. 4-5, pp. 403–412, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. K. Ohtsuka, J. D. Gray, M. M. Stimmler, and D. A. Horwitz, “The relationship between defects in lymphocyte production of transforming growth factor-beta in systemic lupus erythematosus and disease activity or severity,” Lupus, vol. 8, no. 2, pp. 90–94, 1999. View at Google Scholar · View at Scopus
  15. D. A. Horwitz, J. D. Gray, K. Ohtsuka, M. Hirokawa, and T. Takahashi, “The immunoregulatory effects of NK cells: the role of TGF-β and implications for autoimmunity,” Immunology Today, vol. 18, no. 11, pp. 538–542, 1997. View at Google Scholar · View at Scopus
  16. G. G. Illei, Y. Shirota, C. H. Yarboro et al., “Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study,” Arthritis and Rheumatism, vol. 62, no. 2, pp. 542–552, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. W. B. van den Berg, P. L. van Lent, L. A. B. Joosten, S. Abdollahi-Roodsaz, and M. I. Koenders, “Amplifying elements of arthritis and joint destruction,” Annals of the Rheumatic Diseases, vol. 66, supplement 3, pp. iii45–iii48, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. E. M. Moran, R. Mullan, J. McCormick et al., “Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies,” Arthritis Research & Therapy, vol. 11, no. 4, article R113, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. F. Cheng, Z. Guo, H. Xu, D. Yan, and Q. Li, “Decreased plasma IL22 levels, but not increased IL17 and IL23 levels, correlate with disease activity in patients with systemic lupus erythematosus,” Annals of the Rheumatic Diseases, vol. 68, no. 4, pp. 604–606, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. K. Wong, C. Y. Ho, F. W. S. Ko et al., “Proinflammatory cytokines (IL-17, IL-6, IL-18 and IL-12) and Th cytokines (IFN-γ, IL-4, IL-10 and IL-13) in patients with allergic asthma,” Clinical and Experimental Immunology, vol. 125, no. 2, pp. 177–183, 2001. View at Publisher · View at Google Scholar · View at Scopus
  21. J. J. Hooks, H. M. Moutsopoulos, and A. L. Notkins, “Circulating interferon in human autoimmune diseases,” Texas Reports on Biology and Medicine, vol. 41, pp. 164–168, 1981. View at Google Scholar · View at Scopus
  22. S. R. Ytterberg and T. J. Schnitzer, “Serum interferon levels in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 25, no. 4, pp. 401–406, 1982. View at Google Scholar · View at Scopus
  23. T. Kim, Y. Kanayama, N. Negoro, M. Okamura, T. Takeda, and T. Inoue, “Serum levels of interferons in patients with systemic lupus erythematosus,” Clinical and Experimental Immunology, vol. 70, no. 3, pp. 562–569, 1987. View at Google Scholar · View at Scopus
  24. E. Robak, P. Smolewski, A. Wozniacka, A. Sysa-Jedrzejowska, H. Stepień, and T. Robak, “Relationship between peripheral blood dendritic cells and cytokines involved in the pathogenesis of systemic lupus erythematosus,” European Cytokine Network, vol. 15, no. 3, pp. 222–230, 2004. View at Google Scholar · View at Scopus
  25. A. A. Bengtsson, G. Sturfelt, L. Truedsson et al., “Activation of type I interferon system in systemic lupus erythematosus correlates with disease activity but not with antiretroviral antibodies,” Lupus, vol. 9, no. 9, pp. 664–671, 2000. View at Publisher · View at Google Scholar · View at Scopus
  26. M. C. Dall'era, P. M. Cardarelli, B. T. Preston, A. Witte, and J. C. Davis Jr., “Type I interferon correlates with serological and clinical manifestations of SLE,” Annals of the Rheumatic Diseases, vol. 64, no. 12, pp. 1692–1697, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. J. Wenzel, S. Zahn, T. Bieber, and T. Tüting, “Type I interferon-associated cytotoxic inflammation in cutaneous lupus erythematosus,” Archives of Dermatological Research, vol. 301, no. 1, pp. 83–86, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. L. Rönnblom and G. V. Alm, “The natural interferon-α producing cells in systemic lupus erythematosus,” Human Immunology, vol. 63, no. 12, pp. 1181–1193, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Blomberg, M. L. Eloranta, B. Cederblad, K. Nordlind, G. V. Alm, and L. Rönnblom, “Presence of cutaneous interferon-α producing cells in patients with systemic lupus erythematosus,” Lupus, vol. 10, no. 7, pp. 484–490, 2001. View at Publisher · View at Google Scholar · View at Scopus
  30. L. Farkas, K. Beiske, F. Lund-Johansen, P. Brandtzaeg, and F. L. Jahnsen, “Plasmacytoid dendritic cells (natural interferon-α/β-producing cells) accumulate in cutaneous lupus erythematosus lesions,” American Journal of Pathology, vol. 159, no. 1, pp. 237–243, 2001. View at Google Scholar · View at Scopus
  31. B. Cederblad, S. Blomberg, H. Vallin, A. Perers, G. V. Alm, and L. Rönnblom, “Patients with systemic lupus erythematosus have reduced numbers of circulating natural interferon-α-producing cells,” Journal of Autoimmunity, vol. 11, no. 5, pp. 465–470, 1998. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  32. M. Tucci, S. Ciavarella, S. Strippoli, F. Dammacco, and F. Silvestris, “Oversecretion of cytokines and chemokines in lupus nephritis is regulated by intraparenchymal dendritic cells: a review,” Annals of the New York Academy of Sciences, vol. 1173, pp. 449–457, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. P. Blanco, A. K. Palucka, M. Gill, V. Pascual, and J. Banchereau, “Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus,” Science, vol. 294, no. 5546, pp. 1540–1543, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. L. Rönnblom and G. V. Alm, “A pivotal role for the natural interferon α-producing cells (plasmacytoid dendritic cells) in the pathogenesis of lupus,” Journal of Experimental Medicine, vol. 194, no. 12, pp. F59–F63, 2001. View at Google Scholar · View at Scopus
  35. H. M. Lee, T. Mima, H. Sugino et al., “Interactions among type I and type II interferon, tumor necrosis factor, and β-estradiol in the regulation of immune response-related gene expressions in systemic lupus erythematosus,” Arthritis Research & Therapy, vol. 11, no. 1, article R1, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  36. L. Bennett, A. K. Palucka, E. Arce et al., “Interferon and granulopoiesis signatures in systemic lupus erythematosus blood,” Journal of Experimental Medicine, vol. 197, no. 6, pp. 711–723, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  37. E. C. Baechler, F. M. Batliwalla, G. Karypis et al., “Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 5, pp. 2610–2615, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. G. M. Han, S. L. Chen, N. Shen, S. Ye, C. D. Bao, and Y. Y. Gu, “Analysis of gene expression profiles in human systemic lupus erythematosus using oligonucleotide microarray,” Genes and Immunity, vol. 4, no. 3, pp. 177–186, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. T. Ishii, H. Onda, A. Tanigawa et al., “Isolation and expression profiling of genes upregulated in the peripheral blood cells of systemic lupus erythematosus patients,” DNA Research, vol. 12, no. 6, pp. 429–439, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. X. Feng, H. Wu, J. M. Grossman et al., “Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 54, no. 9, pp. 2951–2962, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. J. Alcocer-Varela, D. Aleman-Hoey, and D. Alarcon-Segovia, “Interleukin-1 and interleukin-6 activities are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activation markers,” Lupus, vol. 1, no. 2, pp. 111–117, 1992. View at Google Scholar · View at Scopus
  42. K. Baraczka, K. Nékám, T. Pozsonyi, I. Szüts, and G. Ormos, “Investigation of cytokine (tumor necrosis factor-alpha, interleukin-6, interleukin-10) concentrations in the cerebrospinal fluid of female patients with multiple sclerosis and systemic lupus erythematosus,” European Journal of Neurology, vol. 11, no. 1, pp. 37–42, 2004. View at Publisher · View at Google Scholar
  43. R. Herrera-Esparza, O. Barbosa-Cisneros, R. Villalobos-Hurtado, and E. Avalos-Díaz, “Renal expression of IL-6 and TNFα genes in lupus nephritis,” Lupus, vol. 7, no. 3, pp. 154–158, 1998. View at Publisher · View at Google Scholar
  44. S. H. Lee, S. H. Park, J. K. Min et al., “Decreased tumour necrosis factor-beta production in TNFB2 homozygote: an important predisposing factor of lupus nephritis in Koreans,” Lupus, vol. 6, no. 7, pp. 603–609, 1997. View at Google Scholar
  45. M. Aringer, G. Steiner, W. B. Graninger, E. Höfler, C.W. Steiner, and J. S. Smolen, “Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 56, no. 1, pp. 274–279, 2007. View at Publisher · View at Google Scholar · View at PubMed
  46. A. K. Palucka, J. P. Blanck, L. Bennett, V. Pascual, and J. Banchereau, “Cross-regulation of TNF and IFN-α in autoimmune diseases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 102, no. 9, pp. 3372–3377, 2005. View at Publisher · View at Google Scholar · View at PubMed
  47. K. Miyake, H. Nakashima, M. Akahoshi et al., “Genetically determined interferon-γ production influences the histological phenotype of lupus nephritis,” Rheumatology, vol. 41, no. 5, pp. 518–524, 2002. View at Google Scholar
  48. K. Kim, S. K. Cho, A. Sestak, B. Namjou, C. Kang, and S. C. Bae, “Interferon-gamma gene polymorphisms associated with susceptibility to systemic lupus erythematosus,” Annals of the Rheumatic Diseases. In press. View at Publisher · View at Google Scholar · View at PubMed
  49. M. Funauchi, H. Sugishima, M. Minoda, and A. Horiuchi, “Serum level of interferon-gamma in autoimmune diseases,” The Tohoku Journal of Experimental Medicine, vol. 164, no. 4, pp. 259–267, 1991. View at Google Scholar
  50. W. S. Uhm, K. Na, G. W. Song et al., “Cytokine balance in kidney tissue from lupus nephritis patients,” Rheumatology, vol. 42, no. 8, pp. 935–938, 2003. View at Publisher · View at Google Scholar · View at PubMed
  51. M. Harigai, M. Kawamoto, M. Hara, T. Kubota, N. Kamatani, and N. Miyasaka, “Excessive production of IFN-gamma in patients with systemic lupus erythematosus and its contribution to induction of B lymphocyte stimulator/B cell-activating factor/TNF ligand superfamily-13B,” Journal of Immunology, vol. 181, no. 3, pp. 2211–2219, 2008. View at Google Scholar
  52. C. Haas, B. Ryffel, and M. Le Hir, “IFN-γ receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB×NZW)F1 mice,” Journal of Immunology, vol. 160, no. 8, pp. 3713–3718, 1998. View at Google Scholar
  53. T. Karonitsch, E. Feierl, C. W. Steiner et al., “Activation of the interferon-γ signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells,” Arthritis and Rheumatism, vol. 60, no. 5, pp. 1463–1471, 2009. View at Publisher · View at Google Scholar · View at PubMed
  54. A. T. Masi and R. A. Kaslow, “Sex effects in systemic lupus erythematosus: a clue to pathogenesis,” Arthritis and Rheumatism, vol. 21, no. 4, pp. 480–484, 1978. View at Google Scholar
  55. R. G. Lahita, H. L. Bradlow, J. Fishman, and H. G. Kunkel, “Abnormal estrogen and androgen metabolism in the human with systemic lupus erythematosus,” American Journal of Kidney Diseases, vol. 2, no. 1, supplement 1, pp. 206–211, 1982. View at Google Scholar
  56. M. R. Gubbels Bupp, T. N. Jørgensen, and B. L. Kotzin, “Identification of candidate genes that influence sex hormone-dependent disease phenotypes in mouse lupus,” Genes and Immunity, vol. 9, no. 1, pp. 47–56, 2008. View at Publisher · View at Google Scholar · View at PubMed
  57. C. R. Meier, M. C. J. M. Sturkenboom, A. S. Cohen, and H. Jick, “Postmenopausal estrogen replacement therapy and the risk of developing systemic lupus erythematosus or discoid lupus,” The Journal of Rheumatology, vol. 25, no. 8, pp. 1515–1519, 1998. View at Google Scholar
  58. R. G. Lahita, “Emerging concepts for sexual predilection in the disease systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 876, pp. 64–70, 1999. View at Publisher · View at Google Scholar
  59. A. Doria, L. Iaccarino, P. Sarzi-Puttini et al., “Estrogens in pregnancy and systemic lupus erythematosus,” Annals of the New York Academy of Sciences, vol. 1069, pp. 247–256, 2006. View at Publisher · View at Google Scholar · View at PubMed
  60. A. Doria, M. Cutolo, A. Ghirardello et al., “Steroid hormones and disease activity during pregnancy in systemic lupus erythematosus,” Arthritis Care and Research, vol. 47, no. 2, pp. 202–209, 2002. View at Google Scholar
  61. A. Doria, A. Ghirardello, L. Iaccarino et al., “Pregnancy, cytokines, and disease activity in systemic lupus erythematosus,” Arthritis and Rheumatism, vol. 51, no. 6, pp. 989–995, 2004. View at Google Scholar